Several prominent companies across various sectors have published their unaudited financial results for the third quarter of fiscal year 2026, ended December 31, 2025, in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Financial Highlights

Nectar Lifesciences Limited Performance

Nectar Lifesciences reported mixed financial performance for Q3FY26. The pharmaceutical company's standalone results showed significant variations compared to the previous year.

Nuvama Wealth and Investment Limited Results

Nuvama Wealth and Investment Limited demonstrated strong financial performance across key metrics for the quarter ended December 31, 2025.

The company's nine-month performance showed total income of Rs. 14,757.40 million and net profit after tax of Rs. 2,050.88 million, reflecting strong operational efficiency.

Banking and Financial Services Sector

Suryoday Small Finance Bank Performance

Suryoday Small Finance Bank Limited reported steady growth in its quarterly results for Q3FY26.

Technology Sector Results

Coforge Limited Financial Performance

Coforge Limited showcased robust growth in its technology services business for Q3FY26.

The company's Board of Directors declared an interim dividend of Rs. 4 per equity share during their meeting held on January 22, 2026.

Regulatory Compliance and Approvals

All companies have published their results in accordance with applicable Indian Accounting Standards and regulatory requirements. The financial results have been reviewed by respective Audit Committees and approved by their Boards of Directors. ideaForge Technology Limited's results were approved by the Board on January 22, 2026, while the detailed financial statements are available on stock exchange websites and company portals.

Market Notifications and Corporate Actions

Several companies have also issued important notices alongside their financial results. Solar Industries India Limited announced a postal ballot process for special business resolutions, with remote e-voting scheduled from January 24, 2026, to February 23, 2026. The results of the postal ballot will be announced on or before February 25, 2026.

These quarterly results reflect the diverse performance across sectors, with technology and financial services companies showing particularly strong growth momentum during the third quarter of fiscal year 2026.

Nectar Lifesciences Limited's board of directors approved significant corporate developments during their meeting held on January 23, 2026, including business expansion plans and key appointments that mark a strategic shift for the pharmaceutical company.

Business Expansion Through New MOA

The board approved the adoption of a new set of Memorandum of Association (MOA) to expand the company's business activities beyond its current operations. The proposed amendments include three major business verticals that will diversify the company's revenue streams.

The new MOA encompasses comprehensive construction activities including departmental stores, offices, residential complexes, industrial facilities, entertainment venues, and specialized infrastructure like airports, highways, and Special Economic Zones. The company will also engage in real estate transactions involving land acquisition, development, and property management across India and international markets.

Internal Auditor Appointment

The board appointed M/s. VDR & Associates, Chartered Accountants, as the company's internal auditor for a two-year term covering financial years 2025-26 and 2026-27.

The appointed firm brings extensive experience in providing statutory audits for cooperative banks, scheduled commercial banks, and conducting stock audits, revenue audits, and internal audits for various clients.

Postal Ballot Process

Shareholders will vote on the MOA amendments through a postal ballot process, with the notice to be sent electronically to eligible members. The cut-off date for determining voting eligibility has been set as January 23, 2026, for members whose names appear in the Register of Members or List of Beneficial Owners maintained by the company and depositories.

Meeting Details

The board meeting commenced at 3:00 PM IST and concluded at 4:30 PM IST on January 23, 2026. Company Secretary and Compliance Officer Sanjaymohan Singh Rawat signed the official communication to stock exchanges, ensuring compliance with SEBI regulations.

These strategic decisions position Nectar Lifesciences for significant business diversification while maintaining regulatory compliance through proper internal audit mechanisms and shareholder approval processes.